Chemoradiation treatment with or without concurrent tumor-treating fields (TTFields) therapy in newly diagnosed glioblastoma (GBM) patients in China

• DOI: 10.1186/s41016-025-00391-w
• Publication Date: 2025-03-07T07:04:27Z
• Authors: Liping Liang; Lingchao Chen; Chunxia Ni; Wenyin Shi; Zhirui Zhou; Shu Chen; Wenjia Zhu; Jiabing Liu; Xianxin Qiu; Wanzun Lin; Junyan Zhang; Zhiyong Qin; Yang Wang
• Keywords: Temozolomide

Tumor-treating fields (TTFields) therapy and radiotherapy may have synergistic anti-glioma effect based on preclinical studies. The combination of chemoradiation (CRT) with TTFields has noticeably attracted clinicians' attention. This study aimed to provide insights into the clinical outcomes patients newly diagnosed glioblastoma who received either concurrent CRT or adjuvant following CRT. findings were a cohort treated at Huashan Hospital (Shanghai, China). retrospective analyzed ndGBM patients' therapy. Patients categorized two groups: one group after completing (referred as A-TTF group), while other concurrently continued treatment CA-TTF group). evaluated efficacy toxicities, comparing between groups. Overall survival (OS) progression-free (PFS) using Kaplan-Meier method. To mitigate confounding factors, was assessed Cox proportional hazards regression model, propensity score matching, inverse probability weighting (IPTW) score. A total 72 included in study. Among them, 41 (CA-TTF 31 temozolomide (A-TTF median follow-up time 18.0 months. No significant differences observed PFS (14.2 vs. 15.0 months, P = 0.92) OS (20.8 20.0 Skin toxicity common, manageable, no difference Following IPTW adjustment, hazard ratios for indicated potential advantage group, although this not statistically significant. Concurrent emerged safe GBM patients. Although found groups, benefit warrants further investigation through large-scale trials.